Michael is the Chairman of the Board. He has a PhD in molecular biology from Northwestern University and completed a post-doctoral fellowship in the Department of Microbiology at the University of Illinois Medical Center. After completing his JD at Cornell University, he practiced as a patent attorney at Nixon Peabody, LLP in Rochester. While at Nixon Peabody, he played a significant role in developing the licensing strategy for a major genetic sequencing enterprise, as well as patenting and licensing technologies for several other companies and universities.
Ragu Raman is the President & Chief Operating Officer of the company, responsible for all corporate functions. Prior to joining INT, Mr. Raman worked at Ortho Clinical Diagnostics for five years, most recently as the Head of R&D for Instrument Platforms addressing Clinical Labs & Transfusion Medicine. In this role, he was responsible for leading the technology strategy, product development, and continuous improvements. Prior to joining Ortho, Mr. Raman was the Vice President of R&D at STERIS Corporation for Infection Prevention Technologies serving the Healthcare and Life Science business segments. Mr. Raman also has served as R&D Director at Philips Healthcare in the CT Imaging Systems business, where he led Systems Engineering, and Gantry / X-Ray subsystems development. Mr. Raman also served in multiple positions within GE Healthcare Interventional Cardiology, Surgery and Digital Radiology businesses. Mr. Raman has a Bachelors in Engineering from the Birla Institute of Technology & Science, India and a Masters in Software Engineering from Kansas State University.
Dr. de Mars is currently Senior Director of Commercialization leading efforts towards regulatory approval and market launch of the INT PalladiumTM Test System. Prior to joining INT, Dr. de Mars was Vice-President of the Standards Resource Center (SRC) at ATCC, a business unit focused on standards and related services supporting life science research and development. Prior to ATCC, Dr. de Mars served as Chief Operating Officer and Vice President of Clinical Operations at USDS, Inc., an independent third party evaluating the performance of molecular diagnostic tests to support regulatory, reimbursement and adoption efforts. She also served as Director, Clinical Biomarkers at Critical Path Institute (C-Path), leading collaborative efforts to evaluate and improve the utility of clinical biomarkers and optimize the pathway for development of companion diagnostics. She served as Executive Director of Genomics Services at Gene Logic, Inc. as well as Director of Gene Logic’s biorepository. Dr. de Mars led business development and marketing efforts for several product lines at Life Technologies, Inc., now ThermoFisher Scientific. Dr. de Mars holds a B.A. from Smith College and a Ph.D. in virology from the University of Texas. She completed postdoctoral training in transcriptional regulation at The Johns Hopkins University.